A Phase II Study of Nasal NK/T-Cell Lymphoma
The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by National Health Research Institutes, Taiwan.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Mackay Memorial Hospital
National Cheng-Kung University Hospital
Taichung Veterans General Hospital
Taipei Veterans General Hospital,Taiwan
Kaohsiung Veterans General Hospital.
National Taiwan University Hospital
Tri-Service General Hospital
Chi Mei Medical Hospital
Kaohsiung Medical University
Changhua Christian Hospital
Buddhist Tzu Chi General Hospital
Information provided by:
National Health Research Institutes, Taiwan
ClinicalTrials.gov Identifier:
NCT00292695
First received: February 15, 2006
Last updated: July 2, 2009
Last verified: July 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To determine whether adding combinational chemotherapy concurrently to conventional radiation will improve the response rate, event-free survival, and overall survival.
To test the dose intensity and toxicity of chemotherapy in concurrence with radiation.
To detect the blood EBV DNA level in Chinese Nasal NK/T-cell lymphoma patients and correlate to the treatment response and prognosis.
| Condition | Intervention | Phase |
|---|---|---|
|
Lymphoma |
Drug: Dexamethosone, VP-16, Cisplatin, Ifosfamide, Mesna, IF-RT |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase II Study of Concurrent Chemoradiation for The Localized Nasal NK/T-Cell Lymphoma |
Resource links provided by NLM:
Further study details as provided by National Health Research Institutes, Taiwan:
Primary Outcome Measures:
- tumor response by CT scan or MRI [ Time Frame: the first course of DVIP, one month after the last course of DVIP ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- EBV DNA level, AEs, Withdrawal from the study treatment [ Time Frame: 2-year overall survival and 5-year overall survival , event-free survival, toxicity. ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 30 |
| Study Start Date: | February 2006 |
| Estimated Study Completion Date: | February 2010 |
| Estimated Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Drug: Dexamethosone, VP-16, Cisplatin, Ifosfamide, Mesna, IF-RT
IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1
DVIP: (Q4W, POST-RT) X 2 Dexamethosone 20 mg/m2/d iv D1-4 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-4 Ifosfamide 1.2 gm/m2/d ivd 2 hr D1-4 Mesna 240 mg/m2/d iv at 0, 4, 8 hr D1-4 Cisplatin 20 mg/m2 ivd 1 hr D1-4 G-CSF 250ug subcut D 9-12
Show Detailed Description Eligibility| Ages Eligible for Study: | up to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Histologically proven extranodal NK/T-cell lymphoma, nasal type according to the WHO classification (must be pathology-proven EBV DNA positive as well as cytoplasmic CD3 +, while CD56+ is not an essential diagnostic criteria. ). Newly diagnosed patients.
- Any of lymphomatous involvement exist in nasal cavity and/or paranasal sinuses, orbit, Waldeyer's ring, and oral cavity performance status with ECOG scale 0-2.
- Stage I or contiguous stage II, measurable or evaluable lymphoma by clinical imaging No previous chemotherapy and/or radiotherapy.
- ANC ≧ 2,000/mm3, Platelet ≧ 100,000/mm3 of peripheral blood.
- Age <70.
- Total bilirubin ＜ 2.5 mg/dl, Serum creatinine ≦1.5 mg/dl, Blood urea nitrogen (BUN) ≦ 25 mg/dl
Exclusion Criteria:
1.Pregnancy or lactation period 2.Severe intercurrent illness, eg. Infection, heart failure 3.Myocardial infarction within recent 12 months 4.Known hypersensitivity to any component drug of the treatment regimen
-
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00292695
Contacts
| Contact: Ming-Chih Chang, MD | 886-2-25433535 ext 3454 | mmhdonald@yahoo.com.tw |
| Contact: Yung-Hsin Chin, RN | 886-2-87923311 ext 17643 | yhchin@nhri.org.tw |
Locations
| Taiwan | |
| National Health Research Institutes, Lymphoma Disease Committee | Recruiting |
| Taipei, Taiwan | |
| Contact: Hui-Ju Ch'ang, co-PI, M.D. 886-2-23562959 ext 7678 hjmc@nhri.org.tw | |
| Principal Investigator: Tsu-Yi Chao, M.D. PHD | |
| Principal Investigator: Li-Tzong Chen, M.D.PHD | |
| Principal Investigator: Ann-Lii Cheng, M.D. PHD | |
Sponsors and Collaborators
National Health Research Institutes, Taiwan
Mackay Memorial Hospital
National Cheng-Kung University Hospital
Taichung Veterans General Hospital
Taipei Veterans General Hospital,Taiwan
Kaohsiung Veterans General Hospital.
National Taiwan University Hospital
Tri-Service General Hospital
Chi Mei Medical Hospital
Kaohsiung Medical University
Changhua Christian Hospital
Buddhist Tzu Chi General Hospital
Investigators
| Principal Investigator: | Ming-Chih Chang, M.D. | Lymphoma Disease Committee of Taiwan Cooperative Oncology Group |
More Information
No publications provided
| Responsible Party: | Taiwan Cooperative Oncology Group, National Health Research Instiutes, Taiwan |
| ClinicalTrials.gov Identifier: | NCT00292695 History of Changes |
| Other Study ID Numbers: | T1405 |
| Study First Received: | February 15, 2006 |
| Last Updated: | July 2, 2009 |
| Health Authority: | Taiwan: Department of Health |
Additional relevant MeSH terms:
|
Lymphoma Lymphoma, T-Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin Isophosphamide mustard |
Cisplatin Ifosfamide Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Radiation-Sensitizing Agents Physiological Effects of Drugs Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 23, 2013